Treace Announces Participation at Stifel 2024 Healthcare Conference
Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company focused on surgical treatment of bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, announced its participation in the Stifel 2024 Healthcare Conference. The company's CEO John T. Treace and CFO Mark L. Hair will participate in a fireside chat on November 19, 2024, at 8:00 am ET. A live webcast and replay will be available on the company's investor relations website.
Treace Medical Concepts (NasdaqGS: TMCI), una società di tecnologia medica focalizzata sul trattamento chirurgico dei piedi piatti e delle deformità del mesopiede attraverso le procedure Lapiplasty® e Adductoplasty®, ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference. Il CEO della società, John T. Treace, e il CFO, Mark L. Hair, parteciperanno a un incontro informale il 19 novembre 2024, alle 8:00 ET. Sarà disponibile una diretta web e una registrazione sul sito web dedicato alle relazioni con gli investitori dell'azienda.
Treace Medical Concepts (NasdaqGS: TMCI), una empresa de tecnología médica centrada en el tratamiento quirúrgico de juanetes y deformidades del mediopie a través de sus procedimientos Lapiplasty® y Adductoplasty®, anunció su participación en la Stifel 2024 Healthcare Conference. El CEO de la empresa, John T. Treace, y el CFO, Mark L. Hair, participarán en una charla informal el 19 de noviembre de 2024, a las 8:00 am ET. Una transmisión en vivo y una repetición estarán disponibles en el sitio web de relaciones con inversores de la empresa.
Treace Medical Concepts (NasdaqGS: TMCI)는 Lapiplasty® 및 Adductoplasty® 절차를 통해 족저근막통 및 중족 변형의 외과적 치료에 중점을 둔 의료 기술 회사로, Stifel 2024 Healthcare Conference에 참여한다고 발표했습니다. 회사의 CEO인 John T. Treace와 CFO인 Mark L. Hair는 2024년 11월 19일 오전 8시(ET)에 진행되는 화상 대화에 참석할 예정입니다. 회사의 투자자 관계 웹사이트에서 생중계와 재방송이 제공될 예정입니다.
Treace Medical Concepts (NasdaqGS: TMCI), une entreprise de technologie médicale spécialisée dans le traitement chirurgical des oignons et des déformations du médio-pied grâce à ses procédures Lapiplasty® et Adductoplasty®, a annoncé sa participation à la Stifel 2024 Healthcare Conference. Le PDG de l'entreprise, John T. Treace, et le directeur financier, Mark L. Hair, participeront à une discussion informelle le 19 novembre 2024 à 8h00 ET. Une diffusion en direct et unenregistrement seront disponibles sur le site web des relations avec les investisseurs de l'entreprise.
Treace Medical Concepts (NasdaqGS: TMCI), ein Medizintechnikunternehmen, das sich auf die chirurgische Behandlung von Hallux Valgus und Mittelfußdeformitäten durch seine Verfahren Lapiplasty® und Adductoplasty® spezialisiert hat, gab seine Teilnahme an der Stifel 2024 Healthcare Conference bekannt. Der CEO des Unternehmens, John T. Treace, und der CFO, Mark L. Hair, nehmen am 19. November 2024 um 8:00 Uhr ET an einem informellen Gespräch teil. Ein Live-Stream und eine Aufzeichnung werden auf der Website der Investor Relations des Unternehmens verfügbar sein.
- None.
- None.
PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, beginning at approximately 8:00 am ET.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
When is Treace Medical Concepts (TMCI) presenting at the Stifel 2024 Healthcare Conference?
Who will represent TMCI at the Stifel 2024 Healthcare Conference?
How can investors watch TMCI's presentation at the Stifel Healthcare Conference?
